1. Natural Products
  2. Plants
  3. Araliaceae

Araliaceae

Araliaceae (101):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0603
    20(S)-Ginsenoside Rg3 14197-60-5 98.10%
    20(S)-Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits levels, NF-κB activity, and COX-2 expression.
    20(S)-Ginsenoside Rg3
  • HY-N0605
    Ginsenoside Rh2 78214-33-2 ≥98.0%
    Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
    Ginsenoside Rh2
  • HY-N0039
    Ginsenoside Rb1 41753-43-9 98.75%
    Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65 .
    Ginsenoside Rb1
  • HY-N0045
    Ginsenoside Rg1 22427-39-0 ≥98.0%
    Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
    Ginsenoside Rg1
  • HY-N0835
    (20S)-Protopanaxatriol 34080-08-5 98.35%
    (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and oestrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.
    (20S)-Protopanaxatriol
  • HY-N0798
    20(R)-Protopanaxatriol 1453-93-6
    20(R)-Protopanaxatriol is a natural aglycone of ginsenosides Re, Rf, Rg1, Rg2 and Rh.
    20(R)-Protopanaxatriol
  • HY-N10151
    Notoginsenoside R3 87741-76-2
    Notoginsenoside R3 is an active principle components of P. notoginseng. Notoginsenoside R3 act as a signaling molecule that is associated with various physiological effects. P. notoginseng and its components are used as traditional Chinese medicine for cardiovascular disease.
    Notoginsenoside R3
  • HY-N10152
    Malonylginsenoside Rc 88140-36-7
    Malonylginsenoside Rc is a natural active compound with anti-proliferative activity.
    Malonylginsenoside Rc
  • HY-N2515
    Ginsenoside Rk1 494753-69-4 99.90%
    Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway.
    Ginsenoside Rk1
  • HY-N0044
    Ginsenoside Re 52286-59-6 98.15%
    Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
    Ginsenoside Re
  • HY-N1376
    (20R)-Ginsenoside Rg3 38243-03-7 ≥98.0%
    (20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits vascular endothelial growth factor (VEGF)(IC50=10 nM) and antitumor activities.
    (20R)-Ginsenoside Rg3
  • HY-N0615
    Notoginsenoside R1 80418-24-2 ≥98.0%
    Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells.
    Notoginsenoside R1
  • HY-N0410
    Daucosterol 474-58-8
    Daucosterol is a natural sterolin.
    Daucosterol
  • HY-N0041
    Ginsenoside Rb3 68406-26-8 99.12%
    Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.
    Ginsenoside Rb3
  • HY-N0908
    Ginsenoside Rg5 186763-78-0 99.86%
    Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of IGF-1 to its receptor with an IC50 of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.
    Ginsenoside Rg5
  • HY-N0043
    Ginsenoside Rd 52705-93-8 98.02%
    Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd
  • HY-N0040
    Ginsenoside Rb2 11021-13-9 98.26%
    Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate GPR120 gene expression. Ginsenoside Rb2 has antiviral effects.
    Ginsenoside Rb2
  • HY-N0256
    Hederagenin 465-99-6 ≥98.0%
    Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB.
    Hederagenin
  • HY-N0824
    Syringin 118-34-3 99.05%
    Syringin is a main bioactive phenolic glycoside in Acanthopanax senticosus, with anti-osteoporosis activity. Syringin prevents cardiac hypertrophy induced by pressure overload through the attenuation of autophagy.
    Syringin
  • HY-N0904
    Ginsenoside C-K 39262-14-1 98.04%
    Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
    Ginsenoside C-K